COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,287 Articles (22,759 medRxiv, 8,528 bioRxiv)

Most recent first Previous |  Page 2012: Articles 20111-20120  | Next

Protocol for longitudinal assessment of SARS-CoV-2-specific immune responses in healthcare professionals in Hannover, Germa-ny: the prospective, longitudinal, observational COVID-19 Contact (CoCo) study
Jablonka, A., Happle, C., Cossmann, A., Strankov, M. V., Zychlinsky Scharff, A., Ernst, D., Behrens, G. M.
10.1101/2020.12.02.20242479 — Posted: 2020-12-04
The impact of seasonal respiratory virus transmission on syndromic surveillance for COVID-19 in Ontario, Canada
Maharaj, A. S., Parker, J., Hopkins, J., Tuite, A. R., Brownstein, J. S., Lapointe-Shaw, L., Bogoch, I. I., Fisman, D. N., Rader, B., Gournis, E., Ivers, N. M., Hawkins, J. B., Astley, C. M.
10.1101/2020.12.02.20242735 — Posted: 2020-12-04
Predictive modeling of morbidity and mortality in COVID-19 hospitalized patients and its clinical implications.
Wang, J. M., Liu, W., Chen, X., McRae, M. P., McDevitt, J. T., Fenyo, D.
10.1101/2020.12.02.20235879 — Posted: 2020-12-04
Model for evaluating cost-effectiveness of surveillance testing for SARS-CoV2
Silver, J.
10.1101/2020.12.02.20242644 — Posted: 2020-12-04
THE THERAPEUTIC POTENTIAL OF IVERMECTIN FOR COVID-19: A REVIEW OF MECHANISMS AND EVIDENCE
Kalfas, S., Visvanathan, K., Chan, K., Drago, J.
10.1101/2020.11.30.20236570 — Posted: 2020-12-04
Post-infectious inflammatory disease in MIS-C features elevated cytotoxicity signatures and autoreactivity that correlates with severity
Ramaswamy, A., Brodsky, N. N., Sumida, T. S., Comi, M., Asashima, H., Hoehn, K. B., Li, N., Liu, Y., Shah, A., Ravindra, N. G., Bishai, J., Khan, A., Lau, W., Sellers, B., Bansal, N., Sparks, R., Unterman, A., Habet, V., Rice, A. J., Catanzaro, J., Chandnani, H., Lopez, M., Kaminski, N., Dela Cruz, C. S., Tsang, J. S., Wang, Z., Yan, X., Kleinstein, S. H., van Dijk, D., Pierce, R. W., Hafler, D. A., Lucas, C. L.
10.1101/2020.12.01.20241364 — Posted: 2020-12-04
Unraveling US National COVID-19 Racial/Ethnic Disparities using County Level Data Among 328 Million Americans
Li, D., Gaynor, S. M., Quick, C., Chen, J. T., Stephenson, B. J. K., Coull, B. A., Lin, X.
10.1101/2020.12.02.20234989 — Posted: 2020-12-04
Consistent and High-Frequency Identification of an Intra-Sample Genetic Variant of SARS-CoV-2 with Elevated Fusogenic Properties
Rocheleau, L., Laroche, G., Fu, K., Cote, M., Giguere, P. M., Langlois, M.-A., Pelchat, M.
10.1101/2020.12.03.409714 — Posted: 2020-12-03
Identification of low micromolar SARS-CoV-2 Mpro inhibitors from hits identified by in silico screens
Rossetti, G. G., Ossorio, M., Barriot, S., Tropia, L., Dionellis, V. S., Gorgulla, C., Arthanari, H., Mohr, P., Gamboni, R., Halazonetis, T. D.
10.1101/2020.12.03.409441 — Posted: 2020-12-03
SARS-CoV-2 D614 and G614 spike variants impair neuronal synapses and exhibit differential fusion ability
Chen, C.-Y., Chou, Y.-C., Hsueh, Y.-P.
10.1101/2020.12.03.409763 — Posted: 2020-12-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).